Jonathan Strosberg, MD
Enriched profileProfessor, Department of Gastrointestinal Oncology; Section Head, Neuroendocrine Tumor Division; Chair, Gastrointestinal Department Research Program, Moffitt Cancer Center · Moffitt Cancer Center
Jonathan Strosberg is Professor, Department of Gastrointestinal Oncology; Section Head, Neuroendocrine Tumor Division; Chair, Gastrointestinal Department Research Program, Moffitt Cancer Center at Moffitt Cancer Center. OpenAlex indexes 430 publications with 21,969 citations (h-index 70); ClinicalTrials.gov lists 15 registered studies with this person as an investigator.
Data verified 17 Aug 2026
Overview
Updated 14 Oct 2026
Jonathan Strosberg, MD, is Professor, Department of Gastrointestinal Oncology at Moffitt Cancer Center, Tampa, FL. The public record shows 430 publications with 21,969 citations (h-index 70), centered on Neuroendocrine Tumor Research Advances, Lung Cancer Research Studies, Neuroblastoma Research and Treatments. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 19 companies.
- Most recent indexed publication: 2026 · Endocrine-related cancer
- Top research focus: Neuroendocrine Tumor Research Advances
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 19 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 32 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 197.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
- Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Sponsor: SWOG Cancer Research Network
- Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
Sponsor: AC Camargo Cancer Center
Industry payments
Updated 14 Oct 2026
19 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202510 payments
- Exelixis Inc.Program year202511 payments
- GENZYME CORPORATIONProgram year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
44.1%Serotonin-3 Receptor Antagonist17.3%Ondansetron Hcl100%Part D≥22 patientsProton pump inhibitor8.9%Pantoprazole Sodium52%Omeprazole48%Part D<11 patients+ 4 more classes in this area
Nervous system
40.8%Opioid Agonist26.2%Oxycodone Hcl39%Tramadol Hcl20%Hydromorphone Hcl18%Fentanyl12%Morphine Sulfate Er12%Part D<11 patientsBenzodiazepine5%Lorazepam100%Part D≥13 patients+ 3 more classes in this area
Cardiovascular
7.6%Loop diuretic3.3%Furosemide100%Part D<11 patientsAldosterone antagonist (MRA)2.2%Spironolactone100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Oct 2026
107 congress contributions (2007–2025) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Efficacy of immune checkpoint inhibitors in patients with advanced pancreatic NETs displaying high TMB and MMR alterations following treatment with alkylating agents.
ASCO Annual Meeting
ASCO2025Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602).
Endocrine-related cancer
Clinical Trial2026 - Association Between Long-Term Proton Pump Inhibitor Use and Low-Risk Gastric Neuroendocrine Tumors.
Annals of surgical oncology
Article2026 - Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
JCO oncology practice
Guideline2026 - Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202).
Journal of clinical oncology
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine TumorsArticle3,257 citations2017
- 02
- 03
- 04Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyArticle614 citations2021
- 05Gastroenteropancreatic Neuroendocrine TumorsArticle614 citations2018
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jonathan-strosberg-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Jonathan-Strosberg
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - LinkedIn
linkedin.com/in/jonathan-strosberg-9a819a30
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - Google Scholar
scholar.google.com/citations
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →scholar.google.com ↗
Mentions by others
where others cite or feature them- Other
nanets.net/about/board-of-directors/236-jonathan-r-strosberg-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nanets.net ↗ - Other
carcinoid.org/2022/02/07/dr-jonathan-strosberg-to-be-featured-guest-for-ccfs-luncheon-with-the-experts
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →carcinoid.org ↗ - Other
onclive.com/authors/jonathan-r-strosberg-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Cornell University Medical College
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - Residency
Internal Medicine, Georgetown University Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - Fellowship
Medical Oncology and Hematology, H. Lee Moffitt Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗
Editorial & leadership roles
journal and society appointments- Panel author
ASCO Guideline: Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
2023provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopubs.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nanets.net ↗
- Editorial Board Member
Journal of the National Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →academic.oup.com ↗ - Member
NCCN Neuroendocrine Tumors Guidelines Panel
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →nanets.net ↗ - Professor
Department of Oncologic Sciences, University of South Florida Morsani College of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →nanets.net ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.gov ↗
Secondary affiliations
appointments beyond the home institution- Professor
Department of Oncologic Sciences, University of South Florida Morsani College of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →nanets.net ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- Featured expert
"Neuroendocrine Expert Talks" podcast, discussing carcinoid midgut NET disease progression and treatment strategy
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ignacio Wistuba, MD
Moffitt Cancer Center
Christine Chung, MD
Moffitt Cancer Center
Hatem Soliman, MD
Moffitt Cancer Center
Andrew Brohl, MD
Moffitt Cancer Center
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center